TY - JOUR
T1 - Altered Expression Levels of MicroRNA-132 and Nurr1 in Peripheral Blood of Parkinson's Disease
T2 - Potential Disease Biomarkers
AU - Yang, Zhaofei
AU - Li, Tianbai
AU - Li, Song
AU - Wei, Min
AU - Qi, Hongqian
AU - Shen, Bairong
AU - Chang, Raymond Chuen Chung
AU - Le, Weidong
AU - Piao, Fengyuan
N1 - Funding Information:
*E-mail: piaofengyuan353@163.com (F.P.). *E-mail: wdle@sibs.ac.cn (W.L.). ORCID Bairong Shen: 0000-0003-2899-1531 Raymond Chuen-Chung Chang: 0000-0001-8538-7993 Weidong Le: 0000-0001-7459-2705 Author Contributions W.L. and F.P. designed the project. Z.Y. and T.L. carried out all the experiments. Z.Y., T.L., and B.S. contributed to statistical analyses and results interpretation. Z.Y., T.L., S.L., M.W., and B.S. contributed to drafting of the manuscript. Z.Y., T.L., S.L., M.W., H.Q., R.C.-C.C, W.L., and F.P. revised the paper. All authors edited and approved the final version of the manuscript. Funding This work was supported by the National Basic Research Program of China (81370470), Key Filed Research and Development Program of Guangdong Province (2018B030337001), and National Key Research and Development Program of China (2016YFC1306603). Notes The authors declare no competing financial interest.
Funding Information:
This work was supported by the National Basic Research Program of China (81370470) Key Filed Research and Development Program of Guangdong Province (2018B030337001) and National Key Research and Development Program of China (2016YFC1306603).
Publisher Copyright:
© 2019 American Chemical Society.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/2/28
Y1 - 2019/2/28
N2 - MicroRNAs (miRNAs) are small and evolutionary conserved noncoding RNAs that are involved in post-transcriptional gene regulation. Differential expression levels of miRNAs can be used as potential biomarkers of disease. Previous animal studies have indicated that the expression level of miR-132 is negatively correlated with its downstream molecule nuclear receptor related 1 protein (Nurr1), which is one of the key factors for the maintenance of dopaminergic function and is particularly vulnerable in Parkinson's disease (PD). However, this correlation has not been confirmed in human patients with PD. Moreover, the possible involvement of miR-132 during the pathogenesis and progression of PD is not fully investigated. Therefore, in the present study, we determined the peripheral circulation levels of miR-132 and Nurr1 in patients with PD, neurological disease controls (NDC) and healthy controls (HC) by reverse transcription real-time quantitative PCR (RT-qPCR). Our data clearly demonstrated that the plasma miR-132 level in PD was significantly higher than those in HC (178%, p < 0.05) and NDC (188%, p < 0.001). When adjusted for gender and age, higher level of miR-132 expression was associated with the significantly increased risk for PD in males and was closely related with the disease stages and disease severity. Furthermore, peripheral Nurr1 was significantly decreased in PD compared with HC (56%, p < 0.001) and NDC (58%, p < 0.001). Much more interestingly, further analysis revealed a negative correlation between the decreased Nurr1 level and the elevated miR-132 level in PD. All these findings indicated that the combination of a high miR-132 level with the low level of its downstream Nurr1 might be a potential biomarker aiding in the diagnosis of PD and monitoring disease progression.
AB - MicroRNAs (miRNAs) are small and evolutionary conserved noncoding RNAs that are involved in post-transcriptional gene regulation. Differential expression levels of miRNAs can be used as potential biomarkers of disease. Previous animal studies have indicated that the expression level of miR-132 is negatively correlated with its downstream molecule nuclear receptor related 1 protein (Nurr1), which is one of the key factors for the maintenance of dopaminergic function and is particularly vulnerable in Parkinson's disease (PD). However, this correlation has not been confirmed in human patients with PD. Moreover, the possible involvement of miR-132 during the pathogenesis and progression of PD is not fully investigated. Therefore, in the present study, we determined the peripheral circulation levels of miR-132 and Nurr1 in patients with PD, neurological disease controls (NDC) and healthy controls (HC) by reverse transcription real-time quantitative PCR (RT-qPCR). Our data clearly demonstrated that the plasma miR-132 level in PD was significantly higher than those in HC (178%, p < 0.05) and NDC (188%, p < 0.001). When adjusted for gender and age, higher level of miR-132 expression was associated with the significantly increased risk for PD in males and was closely related with the disease stages and disease severity. Furthermore, peripheral Nurr1 was significantly decreased in PD compared with HC (56%, p < 0.001) and NDC (58%, p < 0.001). Much more interestingly, further analysis revealed a negative correlation between the decreased Nurr1 level and the elevated miR-132 level in PD. All these findings indicated that the combination of a high miR-132 level with the low level of its downstream Nurr1 might be a potential biomarker aiding in the diagnosis of PD and monitoring disease progression.
KW - Nurr1
KW - Parkinson's disease
KW - biomarker
KW - miR-132
KW - peripheral blood
UR - http://www.scopus.com/inward/record.url?scp=85064122673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064122673&partnerID=8YFLogxK
U2 - 10.1021/acschemneuro.8b00460
DO - 10.1021/acschemneuro.8b00460
M3 - Article
C2 - 30817108
AN - SCOPUS:85064122673
VL - 10
SP - 2243
EP - 2249
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
SN - 1948-7193
IS - 5
ER -